The optimal particle size for β-adrenergic aerosols in mild asthmatics

Zanen, Pieter; Go, L. T.; Lammers, Jan‐Willem J.

doi:10.1016/0378-5173(94)90436-7

Cited by 80 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the first of the investigations, by Usmani et al, 83 differed from those of Zanen et al, [79][80][81] because bronchodilator response was found to be higher for 3 μm and 6 μm aerosols than for the 1.5 μm aerosol. However, in a follow-up study, bronchodilator response increased with increasing particle size at an inhaled flow rate of 30 L/min but decreased with increasing particle size at an inhaled flow rate of 67 L/min ( Figure 6).…”

Section: Monodisperse Pharmaceutical Aerosol Studiescontrasting

confidence: 55%

See 1 more Smart Citation

In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review

2007

View full text Add to dashboard Cite

The purpose of this review is to discuss the roles of cascade impactor (CI) data in inhaler assessment and to examine the relationship between aerodynamic particle size distribution (APSD) and the clinical response to inhaled drugs. A systematic literature search of studies linking APSD to clinical response was undertaken. Two distinct roles for CI-generated data were identified: (1) the control of inhaler/drug product quality; and (2) the provision of data that may be predictive of particle deposition in the respiratory tract. Method robustness is required for the former application, combined with simplicity in operation, resulting in rudimentary attempts to mimic the anatomy of the respiratory tract. The latter necessitates making the apparatus and its operation more closely resemble patient use of the inhaler. A CI cannot perfectly simulate the respiratory tract, since it operates at constant flow rate, while the respiratory cycle has a varying flow-time profile. On the basis of a review of studies linking APSD to clinical response of inhaled drugs, it is concluded that attempts to use CIgenerated data from quality control testing to compare products for bioequivalence are likely to have only limited success, as links between laboratory-measured APSD, particle deposition in the respiratory tract, and clinical response are not straightforward.

show abstract

Section: Monodisperse Pharmaceutical Aerosol Studiescontrasting

confidence: 55%

“…In 3 studies, monodisperse bronchodilator aerosols of diameters 1.5 μm, 2.8 μm, and 5.0 μm were compared. [79][80][81] These articles suggest that the optimal bronchodilator particle size in mild asthmatics is ≤ 3 μm and in severe asthmatics is around 3 μm.…”

Section: Monodisperse Pharmaceutical Aerosol Studiesmentioning

confidence: 99%

In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review

2007

View full text Add to dashboard Cite

show abstract

“…A limited number of studies have been published about the relationship between mass median aerodynamic diameter and deposition patterns in the lung, but these have involved small numbers of subjects, showed limitations in methodology, and occasionally led to discrepant conclusions. [19][20][21][22] Thus, currently there is no predictive relationship between changes in APSD and clinical results. Without a clinically defined "permitted difference" or a "gold standard" to which the outcome of the statistical procedure could be compared, the experienced judgment of the WG members using "target profiles" described previously 7 was the best available option.…”

Section: E7mentioning

confidence: 99%

Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 3: Final report on a statistical procedure for determining equivalence

Christopher¹,

Adams

Amann³

et al. 2007

AAPS PharmSciTech

View full text Add to dashboard Cite

The purpose of this article is to report final results of the evaluation of a chi-square ratio test proposed by the US Food and Drug Administration (FDA) for demonstrating equivalence of aerodynamic particle size distribution (APSD) profiles of nasal and orally inhaled drug products. A working group of the Product Quality Research Institute previously published results demonstrating some limitations of the proposed test. In an effort to overcome the test's limited discrimination, the group proposed a supplemental test, a population bioequivalence (PBE) test for impactor-sized mass (ISM). In this final report the group compares the chi-square ratio test to the ISM-PBE test and to the combination of both tests. The basis for comparison is a set of 55 realistic scenarios of cascade impactor data, which were evaluated for equivalence by the statistical tests and independently by the group members. In many instances, the combined application of these 2 tests appeared to increase the discriminating ability of the statistical procedure compared with the chi-square ratio test alone. In certain situations the chi-square ratio test alone was sufficient to determine equivalence of APSD profiles, while in other situations neither of the tests alone nor their combination was adequate. This report describes all of these scenarios and results. In the end, the group did not recommend a statistical test for APSD profile equivalence. The group did not investigate other in vitro tests, in vivo issues, or other statistical tests for APSD profile comparisons. The studied tests are not intended for routine quality control of APSD.

show abstract

“…Several studies were reported on the effect of drug particle size on DPI performance, showing that the preferred drug particle size is between 1-5 µm. 2 However, in literature, the effect of carrier particle size distribution (PSD) on drug aerosolisation efficiency has received less attention and reported in dissimilar manner. 3 Nevertheless, it should be noted that there is rare studies aimed to show the effect of carrier particle size as a single variable factor on DPI performance.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Carrier Particle size on Adhesion, Content Uniformity and Inhalation Performance of Budesonide using Dry Powder Inhalers

Kaialy¹,

Larhrib²,

Nokhodchi³

2011

Particulate Materials

View full text Add to dashboard Cite

The optimal particle size for β-adrenergic aerosols in mild asthmatics

Cited by 80 publications

References 13 publications

In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review

In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review

Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 3: Final report on a statistical procedure for determining equivalence

The Effect of Carrier Particle size on Adhesion, Content Uniformity and Inhalation Performance of Budesonide using Dry Powder Inhalers

Contact Info

Product

Resources

About